Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC

Documenti analoghi

• Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
  di: Paz-Ares, Luis, et al.
  Pubblicazione: (2010)
• Reply to Watkins and Rukazenkov (J Cell Mol Med 2010), re-Letter of Response to manuscript entitled ‘Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis’ (Paz-Ares et al., J Cell Mol Med. 2010; 14(1–2): 51–69)
  di: Paz-Ares, Luis, et al.
  Pubblicazione: (2011)
• ReadMax—a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild‐type non‐small‐cell lung cancer
  di: Moecks, Joachim, et al.
  Pubblicazione: (2015)
• Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI
  di: Cheong, Hio Teng, et al.
  Pubblicazione: (2018)
• Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
  di: Kenichi Koyama, et al.
  Pubblicazione: (2022-04-01)